NEW YORK (GenomeWeb News) – Qiagen secured commercial rights to sell reagents and software for Genome Diagnostics' sequencing based typing technology, Genome Diagnostics said yesterday.
The Dutch company has developed a proprietary strategy for typing human leukocyte antigen genes. Qiagen will have global distribution rights to the technology as of January 2007.
Qiagen already has an exclusive sales and distribution agreement to distribute with Olerup SSP's HLA sequence specific primer technology for HLA typing, Genome Diagnostics said. With this agreement, Qiagen can offer both products to researchers for a complete HLA typing solution.
Financial details were not disclosed.